查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1634215

全球近距离治疗设备市场 - 2025 - 2033

Global Brachytherapy Devices Market - 2025 - 2033
出版日期: | 出版商: DataM Intelligence | 英文 169 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年，全球近距离治疗设备市场规模达到10.241亿美元，预计2033年将达到19.027亿美元，2025-2033年预测期间复合年增长率为7.2%。

近距离放射治疗设备是指用于近距离放射治疗的专用医疗设备，近距离放射治疗是一种内部放射治疗，其中放射源直接放置在肿瘤内部或非常靠近肿瘤。这些设备为肿瘤提供高剂量的辐射，同时最大限度地减少对周围健康组织的照射，使其成为一种有针对性的有效治疗方法，特别是对于局部癌症。近距离放射治疗为各种类型的癌症提供了有效且有针对性的治疗方法。精确性、副作用减少和治疗时间更短使其成为局部癌症患者的宝贵选择。

在癌症盛行率不断上升、技术进步以及对微创治疗的日益偏好等因素的推动下，全球近距离治疗设备市场正在经历显着增长。例如，根据《国际放射肿瘤学、生物学、物理学杂誌》进行的研究，8500 名女性中，36% 只接受了 EBRT，64% 则在 EBRT 的基础上接受了近距离放射治疗。在经历了 2003-2004 年的急剧下降（2003 年最低为 44%）之后，近距离放射治疗的使用率稳步上升，特别是从 2018 年到 2020 年（76%）。

市场动态：

驱动程式和限制

癌症盛行率上升

癌症盛行率的上升极大地推动了近距离治疗设备市场的成长，预计将在预测期内推动该市场的发展。近距离放射治疗对于摄护腺癌、乳癌、子宫颈癌和皮肤癌等局部癌症特别有效。该方法直接向肿瘤提供高剂量的辐射，最大限度地减少对周围健康组织的损害，这对于患有这些不断增加的癌症病例的患者至关重要。例如，根据美国国立卫生研究院的数据，全球死亡的主要原因之一是癌症。全球范围内，2022 年将新增约 2,000 万例癌症病例。

近距离放射治疗被认为是局部前列腺癌的首选治疗方法，尤其是早期肿瘤。它能够提供高辐射剂量，同时对膀胱和直肠等附近器官的损害最小，使其成为针对不断增长的患者群体的高效治疗方法。例如，根据美国癌症协会的估计，2024年美国将新增约299,010例前列腺癌病例。

近距离放射治疗相关的高成本

近距离放射治疗的高成本是阻碍近距离放射治疗设备市场成长的重要因素。该成本的几个方面，包括设备的初始投资、持续维护和放射性材料的成本，都对广泛采用构成了障碍，特别是在医疗保健预算有限的地区。例如，根据 HOSPIDIO 的说法，印度的近距离放射治疗费用从 2000 美元到 4500 美元不等，相当于大约 160000 到 370000 印度卢比。

购买后装机、施药器和治疗计划系统等近距离治疗设备的成本可能从数十万到数百万美元不等。例如，现代近距离放射治疗程序中常用的高剂量率 (HDR) 后装置的成本可能很高，具体取决于型号和技术。

例如，根据美国国立卫生研究院 (NIH) 的数据，2020 年 HDR 后加载器的平均成本将在 200,000 美元至 350,000 美元之间，每年经常性的服务和源交换费用将远远超过 20,000 美元。

目录

第一章：市场介绍和范围

  • 报告的目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按剂量类型分類的片段
  • 按产品类型分類的片段
  • 按技术类型分類的片段
  • 按应用程式片段
  • 最终使用者的片段
  • 按地区分類的片段

第 3 章：动力学

  • 影响因素
    • 司机
      • 癌症盛行率上升
    • 限制
      • 近距离放射治疗的高成本
    • 机会
    • 影响分析

第 4 章：策略洞察与产业展望

  • 市场领导者和先驱
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的知名领导者
    • 拥有成熟产品的市场领导者
  • 新兴新创企业和关键创新者
  • CXO 观点
  • 最新进展和突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态

第 5 章：近距离放射治疗设备市场（按剂量类型）

  • 高剂量率 (HDR) 近距离放射治疗
  • 低剂量率 (LDR) 近距离放射治疗

第 6 章：近距离放射治疗设备市场（依产品类型）

  • 种子
  • 近距离放射治疗枪
  • 近距离治疗后装机
  • 电子近距离放射治疗

第 7 章：近距离放射治疗设备市场（依技术类型）

  • 超音波导引近距离放射治疗
  • 磁振造影 (MRI) 引导近距离放射治疗
  • 电脑断层扫描 (CT) 导引近距离放射治疗
  • 正子断层扫描 (PET) 导引近距离放射治疗
  • 其他的

第 8 章：近距离放射治疗设备市场（按应用）

  • 摄护腺癌
  • 皮肤癌
  • 妇科癌症
  • 乳癌
  • 子宫颈癌
  • 其他的

第 9 章：近距离放射治疗设备市场（依最终用户）

  • 医院
  • 诊断中心
  • 放射治疗中心
  • 门诊手术中心
  • 其他的

第 10 章：近距离放射治疗设备市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的主要发展
  • 公司基准化分析

第 12 章：公司简介

  • Elekta AB
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
    • SWOT分析
  • Varian Medical Systems, Inc.
  • Eckert & Ziegler
  • Theragenics Corporation
  • Becton, Dickinson, and Company
  • BEBIG Medical
  • Sun Nuclear Corporation
  • CIVCO Medical Solutions

第 13 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 14 章：附录

简介目录
Product Code: MD7683

The global brachytherapy devices market reached US$ 1,024.1 million in 2024 and is expected to reach US$ 1,902.7 million by 2033, growing at a CAGR of 7.2% during the forecast period 2025-2033.

Brachytherapy devices refer to specialized medical devices used in brachytherapy, a form of internal radiation therapy where radioactive sources are placed directly inside or very close to a tumor. The devices deliver a high dose of radiation to the tumor while minimizing exposure to surrounding healthy tissues, making it a targeted and effective treatment, especially for localized cancers. Brachytherapy offering an effective and targeted treatment method for various types of cancer. The precision, reduced side effects and shorter treatment times make it a valuable option for patients with localized cancers.

The global brachytherapy devices market is experiencing significant growth, driven by factors such as the increasing prevalence of cancer, technological advancements and a rising preference for minimally invasive treatments. For instance, according to the study conducted by International Journal of Radiation Oncology, Biology, Physics, of the 8500 women, 36% underwent EBRT alone, and 64% received brachytherapy in addition to EBRT. After a steep fall in 2003-2004 (with the lowest rate of 44% in 2003), the brachytherapy usage rate steadily increased, particularly from 2018 to 2020 (76%).

Market Dynamics: Drivers & Restraints

Rising prevalence of cancer

The rising prevalence of cancer is significantly driving the growth of the brachytherapy devices market and is expected to drive the market over the forecast period. Brachytherapy is particularly effective for localized cancers like prostate, breast, cervical and skin cancers. The method delivers high doses of radiation directly to the tumor, minimizing damage to surrounding healthy tissue, which is crucial for patients suffering from these increasing cancer cases. For instance, according to the National Institute of Health, one of the main causes of mortality in the globe is cancer. Globally, there were about 20 million new cases in 2022. It is anticipated that there will be 29.9 million new cancer cases year by 2040.

Brachytherapy is considered a preferred treatment for localized prostate cancer, particularly in early-stage tumors. Its ability to provide a high radiation dose with minimal damage to nearby organs, such as the bladder and rectum, makes it a highly effective treatment method for this growing patient population. For instance, according to the American Cancer Society's estimates in the United States in 2024, about 299,010 new cases of prostate cancer.

High cost associated with brachytherapy

The high cost associated with brachytherapy is a significant factor that hampers the growth of the brachytherapy devices market. Several aspects of this cost, including the initial investment in equipment, ongoing maintenance and the cost of radioactive materials, present barriers to widespread adoption, particularly in regions with limited healthcare budgets. For instance, according to the HOSPIDIO, brachytherapy cost in India can range from $2000 to $4500, which is equivalent to approximately 1,60,000 to 3,70,000 Indian rupees.

The cost of purchasing brachytherapy equipment such as afterloaders, applicators, and treatment planning systems can range from hundreds of thousands to millions of dollars. For instance, a high-dose rate (HDR) afterloader, which is commonly used in modern brachytherapy procedures, can cost high depending on the model and technology.

For instance, according to the National Institute of Health (NIH), an HDR afterloader will cost between USD 200,000 and USD 350,000 on average in 2020, with recurring yearly servicing and source exchange expenses of well over USD 20,000.

Segment Analysis

The global brachytherapy devices market is segmented based on dosage type, product type, technique type, application, end-user and region.

Dosage Type:

The High-Dose Rate (HDR) brachytherapy segment is expected to dominate the brachytherapy devices market share

High-Dose Rate (HDR) brachytherapy allows for the delivery of a high dose of radiation in a short period, enabling precise targeting of the tumor. This results in better tumor control with minimal damage to surrounding healthy tissue. HDR brachytherapy sessions are typically much shorter than those of Low Dose Rate (LDR), which makes it more convenient for both patients and healthcare providers. HDR treatments can be completed within a few minutes per session, whereas LDR treatments can span several days.

High-Dose Rate (HDR) brachytherapy is widely used in the treatment of localized prostate cancer. In prostate cancer treatment, HDR has shown comparable, if not superior, outcomes to LDR in terms of tumor control, with a shorter treatment duration.

For instance, in July 2024, GE HealthCare's MIM Software introduced MIM Symphony HDR Prostate to support high dose-rate (HDR) brachytherapy. By offering direct tumor visualization from magnetic resonance imaging (MRI) images during live ultrasound operations for HDR prostate treatments, this novel technology seeks to boost clinician confidence and contribute to better patient outcomes. By providing MRI guiding and correcting MRI alignment during HDR prostate treatments, MIM Symphony HDR Prostate distinguishes itself in the industry.

Geographical Analysis

North America is expected to hold a significant position in the brachytherapy devices market share

According to the American Cancer Society, approximately 1.9 million new cancer cases were expected to be diagnosed in the United States in 2023, with prostate, breast, and gynecological cancers being some of the most common. This rising cancer burden creates a growing demand for effective, targeted treatments like brachytherapy.

The U.S. has one of the highest incidences of prostate cancer globally, with an estimated 1 in 8 men being diagnosed. Brachytherapy, particularly HDR brachytherapy, is a leading treatment choice for localized prostate cancer, contributing significantly to the growth of the brachytherapy devices market.

North America has seen significant adoption of high-dose rate (HDR) brachytherapy devices, which offer superior precision and faster treatment times. The use of real-time imaging, automated afterloaders, and improved treatment planning systems are particularly prevalent in this region, enhancing the effectiveness of brachytherapy treatments.

Companies like Varian Medical Systems, Elekta and other emerging players are based in North America and lead the development of next-generation brachytherapy devices. These innovations ensure that North American healthcare providers are equipped with the most advanced technologies available.

Asia-Pacific is growing at the fastest pace in the brachytherapy devices market

The APAC region has seen a significant rise in cancer cases due to factors such as population growth, aging populations, urbanization, and lifestyle changes. According to the International Agency for Research on Cancer (IARC), Asia accounted for 47% of the global cancer burden in 2020. Countries like China, India, and Japan have some of the highest cancer rates globally. This surge in cancer cases is driving demand for effective treatments like brachytherapy.

Governments in APAC countries are increasingly investing in healthcare infrastructure, including cancer treatment facilities. This investment is critical for expanding access to advanced therapies like brachytherapy. For instance, the Indian government's focus on improving healthcare access and cancer treatment capabilities has resulted in greater availability of brachytherapy devices in the country.

As patients in the APAC region increasingly demand minimally invasive treatment options, the adoption of brachytherapy continues to rise. Its ability to deliver targeted radiation with reduced risk of side effects and shorter recovery times makes it an attractive treatment option. For instance, in South Korea, patients are becoming more inclined toward advanced cancer therapies like HDR brachytherapy, which requires fewer hospital visits and allows for faster recovery compared to traditional external beam radiation therapy.

Competitive Landscape

The major global players in the brachytherapy devices market include Elekta AB, Varian Medical Systems, Inc., Eckert & Ziegler, Theragenics Corporation, Becton, Dickinson, and Company, BEBIG Medical, Sun Nuclear Corporation, CIVCO Medical Solutions and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global brachytherapy devices market report delivers a detailed analysis with 72 key tables, more than 77 visually impactful figures, and 169 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Dosage Type
  • 2.4. Snippet by Product Type
  • 2.5. Snippet by Technique Type
  • 2.6. Snippet by Application
  • 2.7. Snippet by End-User
  • 2.8. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Cancer
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of Brachytherapy
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Brachytherapy Devices Market, By Dosage Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
    • 5.1.2. Market Attractiveness Index, By Dosage Type
  • 5.2. High-Dose Rate (HDR) Brachytherapy*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Low-Dose Rate (LDR) Brachytherapy

6. Brachytherapy Devices Market, By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Seeds*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Brachytherapy Applicators
  • 6.4. Brachytherapy Afterloaders
  • 6.5. Electronic Brachytherapy

7. Brachytherapy Devices Market, By Technique Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique Type
    • 7.1.2. Market Attractiveness Index, By Technique Type
  • 7.2. Ultrasound-Guided Brachytherapy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Magnetic Resonance Imaging (MRI)-Guided Brachytherapy
  • 7.4. Computed Tomography (CT)-Guided Brachytherapy
  • 7.5. Positron Emission Tomography (PET)-Guided Brachytherapy
  • 7.6. Others

8. Brachytherapy Devices Market, By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Prostate Cancer*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Skin Cancer
  • 8.4. Gynecological Cancer
  • 8.5. Breast Cancer
  • 8.6. Cervical Cancer
  • 8.7. Others

9. Brachytherapy Devices Market, By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Diagnostic Centers
  • 9.4. Radiotherapy Centers
  • 9.5. Ambulatory Surgical Centers
  • 9.6. Others

10. Brachytherapy Devices Market, By Regional Market Analysis and Growth Opportunities

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique Type
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.8.1. U.S.
      • 10.2.8.2. Canada
      • 10.2.8.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique Type
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.8.1. Germany
      • 10.3.8.2. U.K.
      • 10.3.8.3. France
      • 10.3.8.4. Spain
      • 10.3.8.5. Italy
      • 10.3.8.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique Type
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.8.1. Brazil
      • 10.4.8.2. Argentina
      • 10.4.8.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique Type
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.8.1. China
      • 10.5.8.2. India
      • 10.5.8.3. Japan
      • 10.5.8.4. South Korea
      • 10.5.8.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique Type
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape and Market Positioning

  • 11.1. Competitive Overview and Key Market Players
  • 11.2. Market Share Analysis and Positioning Matrix
  • 11.3. Strategic Partnerships, Mergers & Acquisitions
  • 11.4. Key Developments in Product Portfolios and Innovations
  • 11.5. Company Benchmarking

12. Company Profiles

  • 12.1. Elekta AB*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
    • 12.1.5. SWOT Analysis
  • 12.2. Varian Medical Systems, Inc.
  • 12.3. Eckert & Ziegler
  • 12.4. Theragenics Corporation
  • 12.5. Becton, Dickinson, and Company
  • 12.6. BEBIG Medical
  • 12.7. Sun Nuclear Corporation
  • 12.8. CIVCO Medical Solutions

LIST NOT EXHAUSTIVE

13. Assumption and Research Methodology

  • 13.1. Data Collection Methods
  • 13.2. Data Triangulation
  • 13.3. Forecasting Techniques
  • 13.4. Data Verification and Validation

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us